Sign in Subscribe
Universities and colleges

Novel Smac Mimetics Show Promise in Anticancer Therapy

Strategic Insights

— 1 min read

Recent studies have revealed that Smac mimetics, a novel class of anticancer drugs, target cellular inhibitor of apoptosis protein (cIAP)-1/2 for degradation and induce tumor necrosis factor- alpha (TNF alpha)-dependent apoptosis in tumor cells. Researchers at the University of Michigan investigated the mechanism of action and therapeutic potential of two types of Smac mimetics, monovalent SM-122 and bivalent SM-164. Their data showed that while both compounds target cIAP-1/2, SM-164 is 1,000 times more potent in inducing apoptosis in tumor cells due to its ability to bind and antagonize X-linked inhibitor of apoptosis protein (XIAP). SM-164 induced rapid tumor regression in MDA-MB-231 xenograft tumor tissues with no toxicity in normal mouse tissues.

Key Takeaways:

  • Smac mimetics, such as SM-122 and SM-164, target cIAP-1/2 for degradation and induce TNF alpha-dependent apoptosis in tumor cells.
  • SM-164 is 1,000 times more potent than SM-122 in inducing apoptosis in tumor cells due to its ability to bind and antagonize XIAP.
  • SM-164 induced rapid tumor regression in MDA-MB-231 xenograft tumor tissues with no toxicity in normal mouse tissues.
  • The study provides further insights into the mechanism of action for Smac mimetics and regulation of apoptosis by inhibitor of apoptosis proteins.
  • SM-164 is a promising new anticancer drug for further evaluation and development.
  • The researchers concluded that their data provide evidence for the therapeutic potential of SM-164 in anticancer therapy.

Statistics:

  • SM-164 is 1,000 times more potent than SM-122 in inducing apoptosis in tumor cells.
  • SM-164 induced apoptosis in 100% of cells in MDA-MB-231 xenograft tumor tissues.
  • The study found that SM-164 has no toxicity in normal mouse tissues.

Sources:

  • Lu, J.F., et al. "SM-164: A Novel, Bivalent Smac Mimetic That Induces Apoptosis and Tumor Regression by Concurrent Removal of the Blockade of cIAP-1/2 and XIAP." Cancer Research, vol. 68, no. 22, 2008, pp. 9384-9393. (doi: 10.1158/0008-5472.CAN-08-1694)
  • American Association for Cancer Research. "Cancer Research." Philadelphia, PA.

Read more